New guidelines and the continuous modification of current policies will be needed in order to establish and maintain an appropriate professional relationship between physicians and pharmaceutical companies.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.